ArticleProceedings of the National Academy of Sciences of the United States of America2011
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 267 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
267 citing papers in PubMed, 2 syntheses or guidelines pooled it, 466 citations in OpenAlex.
- Analysis of mutations in cutaneous squamous cell carcinoma reveals novel genes and mutations associated with patient-specific characteristics and metastasis: a systematic review.Archives of dermatological research · 2022Pooled it
- Functional Gene Expression Differentiation of the Notch Signaling Pathway in Female Reproductive Tract Tissues-A Comprehensive Review With Analysis.Frontiers in cell and developmental biology · 2020Pooled it
- Trial
- Loss of ZNF750 in ocular and cutaneous sebaceous carcinoma.Journal of cutaneous pathology · 2019Trial
- A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.Oncotarget · 2017Trial
- NOTCH pathway inactivation promotes bladder cancer progression.The Journal of clinical investigation · 2015Trial
- mRNA Therapeutics for Skin Rejuvenation: From Aging Atlases to Clinical Translation.Experimental dermatology · 2026Review
- Evaluation of the subtype-specific epigenetic prognostic association of HELLS in non-small cell lung cancer: integrated clinical and molecular insights.Translational cancer research · 2026Article
- Prognostic significance of positive margin-informed tumor status in esophageal squamous cell carcinoma using next-generation sequencing.The oncologist · 2026Article
- CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.Cell death & disease · 2026Article
- SFTPB Expression Predicts Favorable Survival in Lung Adenocarcinoma but Poor Prognosis in Lung Squamous Cell Carcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer.JCI insight · 2026Article
- Distinct molecular pathogenesis in the two most common subtypes of cutaneous squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2026Article
- Review
- CDKN2A, ITGA3, SMAD4 and SIRT7 gene expression in human cutaneous squamous cell carcinoma development and pre-clinical diagnosis.BMC cancer · 2026Article
- Genomic Insights into Cutaneous Squamous Cell Carcinoma.Cancers · 2026Article
- SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.International journal of molecular sciences · 2026Review
- The dual role of the Notch signaling pathway in digestive system cancers.European journal of medical research · 2026Review
- The dynamics of mutational selection in cutaneous squamous carcinogenesis.Communications biology · 2026Article
- Solute carrier family (SLC) amino acid transporters are upregulated in cutaneous squamous cell carcinoma.Biology direct · 2026Article
207 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 9 institutions in 3 countries.
Funding
Abstract
Squamous cell carcinomas (SCCs) are one of the most frequent forms of human malignancy, but, other than TP53 mutations, few causative somatic aberrations have been identified. We identified NOTCH1 or NOTCH2 mutations in ~75% of cutaneous SCCs and in a lesser fraction of lung SCCs, defining a spectrum for the most prevalent tumor suppressor specific to these epithelial malignancies. Notch receptors normally transduce signals in response to ligands on neighboring cells, regulating metazoan lineage selection and developmental patterning. Our findings therefore illustrate a central role for disruption of microenvironmental communication in cancer progression. NOTCH aberrations include frameshift and nonsense mutations leading to receptor truncations as well as point substitutions in key functional domains that abrogate signaling in cell-based assays. Oncogenic gain-of-function mutations in NOTCH1 commonly occur in human T-cell lymphoblastic leukemia/lymphoma and B-cell chronic lymphocytic leukemia. The bifunctional role of Notch in human cancer thus emphasizes the context dependency of signaling outcomes and suggests that targeted inhibition of the Notch pathway may induce squamous epithelial malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.